New hires at Brii, Ono and PharmaEssentia to strengthen U.S. leadership

Infectious and CNS disease company Brii Biosciences Ltd. (HKEX:2137) hired Coy Stout as SVP and head of U.S. market access and patient advocacy. Stout joins from Gilead Sciences Inc. (NASDAQ:GILD), where he worked for 17 years in several roles, most recently as VP of U.S. commercial access and reimbursement. The company went public on the Hong Kong stock exchange in July.

Ono Pharma USA Inc., the U.S. subsidiary of Ono Pharmaceutical Co. Ltd. (Tokyo:4528), hired David Trexler as chief commercial officer. Trexler, an 18-year veteran of Sanofi (Euronext:SAN; NASDAQ:SNY), was president and board member at MorphoSys US Inc., and previously held leadership roles at EMD Serono Inc., a part of Merck KGaA (Xetra:MRK), and at Eisai US...